Skip to content
Clinical Trials – home
AustriaBack to Austria

Clinical trials in Rankweil – page 8

103 clinical trials in Rankweil, Austria. Every trial is listed in the EU Clinical Trials Register and updated daily.

Rankweil at a glance
103
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

103 trials in Rankweil

Open in trial search

Gastric cancer

Not recruiting

Study of Bemarituzumab with Chemotherapy and Nivolumab in Untreated Advanced Gastric and Gastroesophageal Junction Cancer Patients with FGFR2b Overexpression

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Bemarituzumab
  • Sponsor:Amgen Inc.

Study of Datopotamab Deruxtecan and Durvalumab for Adults with Untreated Triple-Negative or Hormone Receptor-Low/HER2-Negative Breast Cancer

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Astrazeneca AB

Study Comparing Camizestrant and Palbociclib with Anastrozole and Palbociclib for Patients with ER-Positive, HER2-Negative Advanced Breast Cancer Without Prior Treatment

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Anastrozole
  • Sponsor:Astrazeneca AB

Study on Tafasitamab and Lenalidomide with Standard Therapy for Newly Diagnosed High-Risk Diffuse Large B-Cell Lymphoma Patients

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Cyclophosphamide
  • Sponsor:Incyte Corp.

Study of Selpercatinib for Patients with Early-Stage RET Fusion-Positive Non-Small Cell Lung Cancer After Local Treatment

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Selpercatinib
  • Sponsor:Eli Lilly & Co.

Study of Datopotamab Deruxtecan, Durvalumab, and Carboplatin for Advanced Non-Small Cell Lung Cancer in Patients Without Actionable Genomic Alterations

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Astrazeneca AB

Study of Pembrolizumab for Patients with Early Stage Non-Small Cell Lung Cancer After Surgery and Standard Therapy

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Merck Sharp & Dohme LLC

Plasma cell myeloma

Not recruiting

Study of Teclistamab and Lenalidomide as Maintenance Treatment for Newly Diagnosed Multiple Myeloma Patients After Stem Cell Transplantation

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Lenalidomide
  • Sponsor:Emn Trial Office S.r.l. Impresa Sociale

Dermatitis atopic

Not recruiting

Study on Dose Flexibility of Upadacitinib for Adults with Moderate to Severe Atopic Dermatitis

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years
  • Substances:Upadacitinib
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Atrial fibrillation+2

Not recruiting

Study on Asundexian and Apixaban for Preventing Stroke in Adults with Atrial Fibrillation at Risk for Stroke

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Apixaban
  • Sponsor:Bayer AG

Hand dermatitis

Not recruiting

Study on the Effectiveness and Safety of Ruxolitinib Cream for Adults with Chronic Hand Eczema

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Ruxolitinib
  • Sponsor:Incyte Corp.

Pruritus+1

Not recruiting

Study on the Effectiveness and Safety of Difelikefalin for Adults with Moderate-to-Severe Itching from Notalgia Paresthetica

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Difelikefalin
  • Sponsor:Cara Therapeutics Inc.

Other cities in Austria

The busiest research cities in the country

All 48 cities in Austria

Clinical research in Rankweil

What the registry says about research in the country

01 Lung Cancer Research

Groundbreaking studies focusing on both small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC), evaluating innovative combination therapies and treatment approaches.

  • Extensive-Stage SCLC Treatment
  • Early-Stage NSCLC Management
  • Advanced NSCLC Therapies

Multiple trials exploring immunotherapy combinations with chemotherapy for improved patient outcomes.

02 Surgical Oncology

Research investigating perioperative treatment strategies for resectable lung cancer, combining innovative immunotherapy approaches with standard surgical interventions.

  • Pre-surgical Immunotherapy
  • Post-operative Treatment
  • Combined Modality Approaches

Studies aim to enhance surgical outcomes and prevent disease recurrence in operable cases.

03 Hematologic Oncology

Innovative research in multiple myeloma treatment, evaluating novel therapeutic combinations for transplant-ineligible patients with newly diagnosed disease.

  • Novel Drug Combinations
  • First-line Therapies
  • Treatment Optimization

Focus on improving treatment responses and patient outcomes in blood cancer management.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.